Robocath

Executive Summary

Robocath is a French medical device company pioneering robotic-assisted solutions for interventional cardiovascular procedures, with its flagship product R-One+ designed to enhance precision and safety in percutaneous coronary interventions (PCI). Founded in 2009 and based in Rouen, the company addresses a critical need for improved outcomes in treating heart attacks and strokes through a smart, connected robotic system that assists physicians during complex angioplasties. With an experienced team and a clear focus on interventional cardiology, Robocath has positioned itself as a key player in the growing robotic cath lab market, which is expected to expand as hospitals seek to improve procedural consistency and reduce radiation exposure for clinicians. The company has likely achieved CE marking for R-One+ in Europe and is pursuing FDA clearance for the US market, which represents a significant growth opportunity. Robocath may also be exploring strategic partnerships with leading catheterization lab equipment manufacturers or engaging in post-market clinical studies to validate the system's benefits. Given the increasing adoption of robotics in minimally invasive surgery and the company's niche focus, Robocath shows promise for commercial success, though it faces competition from established players. A moderate conviction score of 65 reflects the potential upside balanced against regulatory and market adoption risks.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval of R-One+ for US Market50% success
• TBDPositive Results from Pivotal Clinical Trial60% success
• Q4 2026Strategic Partnership or Distribution Agreement with Major Cardiology OEM40% success